Healthpeak Properties reported a solid QQ3 2024 performance characterized by ongoing earnings growth across its diversified healthcare real estate portfolio, led by strength in the lab and outpatient medical segments and a merger that continues to unlock operating leverage and cost efficiencies. The company raised its guidance for FFO per share (FFO) to $1.79–$1.81 and AFFO per share to $1.56–$1.58, reflecting better-than-forecast same-store performance, higher merger synergies, and stronger leasing momentum. Management highlighted four levers of growth: (1) merger-related internalization and synergies, (2) lab leasing momentum, (3) outpatient medical development and leasing, and (4) a disciplined capital allocation framework including structured investments that can provide immediate accretion while preserving balance-sheet strength. The quarter showcased improved occupancy in the lab portfolio, record lease activity in the outpatient space, and high-quality execution on redevelopments and pre-leased development with attractive yields.